Parkman Healthcare Partners LLC Sells 23,128 Shares of Viridian Therapeutics, Inc. $VRDN

Key Points

• Parkman Healthcare Partners LLC has reduced its stake in Viridian Therapeutics by 2.1%, now holding approximately 1.3% of the company's shares, which amounts to $14.35 million.
• Other investors like Amalgamated Bank and GAMMA Investing LLC have significantly increased their stakes in Viridian Therapeutics by 49.7% and 3,892.9%, respectively.
• Viridian Therapeutics reported a quarterly EPS of ($1.00), matching analyst expectations, with a slight year-over-year revenue increase of 4.2% to $0.08 million.

Parkman Healthcare Partners LLC trimmed its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 2.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,064,506 shares of the company's stock after selling 23,128 shares during the quarter. Viridian Therapeutics makes up about 1.7% of Parkman Healthcare Partners LLC's investment portfolio, making the stock its 24th largest holding. Parkman Healthcare Partners LLC owned approximately 1.30% of Viridian Therapeutics worth $14,350,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Amalgamated Bank lifted its holdings in shares of Viridian Therapeutics by 49.7% during the 1st quarter. Amalgamated Bank now owns 2,531 shares of the company's stock valued at $34,000 after buying an additional 840 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Viridian Therapeutics by 3,892.9% during the 1st quarter. GAMMA Investing LLC now owns 8,425 shares of the company's stock valued at $114,000 after acquiring an additional 8,214 shares during the last quarter. EntryPoint Capital LLC acquired a new position in shares of Viridian Therapeutics during the 1st quarter valued at about $185,000. Brevan Howard Capital Management LP acquired a new position in shares of Viridian Therapeutics during the 4th quarter valued at about $258,000. Finally, Quantbot Technologies LP increased its holdings in shares of Viridian Therapeutics by 146.4% during the 1st quarter. Quantbot Technologies LP now owns 21,131 shares of the company's stock valued at $285,000 after acquiring an additional 12,556 shares during the last quarter.

Viridian Therapeutics Stock Performance

NASDAQ VRDN traded up $0.40 during trading on Tuesday, hitting $20.21. The company's stock had a trading volume of 1,175,086 shares, compared to its average volume of 851,003. The company has a quick ratio of 11.01, a current ratio of 11.01 and a debt-to-equity ratio of 0.04. The firm has a 50 day moving average price of $17.60 and a 200 day moving average price of $15.27. The firm has a market cap of $1.65 billion, a P/E ratio of -5.28 and a beta of 0.53. Viridian Therapeutics, Inc. has a 52 week low of $9.90 and a 52 week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($1.00) EPS for the quarter, hitting the consensus estimate of ($1.00). Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%.The company had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.05 million. During the same period in the previous year, the business posted ($0.81) EPS. The company's revenue for the quarter was up 4.2% on a year-over-year basis. Equities research analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on VRDN shares. Wells Fargo & Company lowered their price objective on Viridian Therapeutics from $27.00 to $26.00 and set an "equal weight" rating on the stock in a report on Thursday, August 7th. Royal Bank Of Canada lowered their price objective on Viridian Therapeutics from $45.00 to $41.00 and set an "outperform" rating on the stock in a report on Thursday, August 7th. Jefferies Financial Group started coverage on Viridian Therapeutics in a report on Monday, August 25th. They set a "buy" rating and a $44.00 price objective on the stock. The Goldman Sachs Group increased their price objective on Viridian Therapeutics from $27.00 to $30.00 and gave the company a "buy" rating in a report on Thursday, August 7th. Finally, Oppenheimer increased their price objective on Viridian Therapeutics from $28.00 to $32.00 and gave the company an "outperform" rating in a report on Thursday, August 7th. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Viridian Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $37.78.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.